Treatment
Keytruda’s New FDA Approval for Mesothelioma: A Breakthrough in Treatment
The U.S. Food and Drug Administration (FDA) has recently expanded the use of Keytruda (pembrolizumab), an immunotherapy drug, marking a significant advancement in the treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). Approved on September 17, 2024, the combination of Keytruda with pemetrexed and platinum-based chemotherapy offers new hope to mesothelioma patients, who…
Read MoreCommon Questions About Mesothelioma
Mesothelioma is a type of cancer that develops in the mesothelial cells, which form the protective lining around the lungs, abdomen, and heart. The disease is closely associated with asbestos exposure, as inhaling or ingesting asbestos fibers can lead to the development of cancerous cells over time. Causes and Risk FactorsThe cause of mesothelioma is exposure…
Read MoreHigh-Risk Individuals May Consider Mesothelioma Screening for Early Detection
Mesothelioma is a rare and aggressive form of cancer that primarily affects the lining of the lungs (pleura) and, in some cases, the lining of the abdomen (peritoneum). It’s only cause is asbestos exposure, with a significant latency period between the time of initial exposure disease development. As the symptoms of mesothelioma often resemble other…
Read More